YHLO Helps China’s Top Ranking Hospital PUMCH to Upgrade from Traditional ELISA to CLIA Technology
|
By LabMedica International staff writers Posted on 06 Jan 2021 |
|
Image: iModules Integration System for Immunoassay (Photo courtesy of Shenzhen YHLO Biotech Co., Ltd.)
Shenzhen YHLO Biotech Co., Ltd. (Shenzhen, China) has helped China’s top ranking hospital, Peking Union Medical College Hospital (PUMCH; Beijing, China), to successfully upgrade its laboratory from the traditional ELISA (enzyme-linked immunoassay) technology to CLIA (chemiluminescence immunoassay) technology.
PUMCH, founded by the Rockefeller Foundation in 1921, has been designated by China’s Ministry of Health as one of the most authoritative centers for diagnosis and treatment of complex diseases. PUMCH’s department of Rheumatology and Immunology is the earliest dedicated department for rheumatology and immunology in China. The department’s laboratory is capable of diagnosing nearly 100 kinds of auto-antibodies, making it one of the largest auto-antibody diagnosing centers in China. In August 2020, the department upgraded its laboratory from the traditional ELISA technology to CLIA technology with the cooperation of YHLO.
With the help of YHLO’s iModules Integration System for Immunoassay, PUMCH has become the first among the top Chinese hospitals to establish a fully automated assembly line. YHLO’s iModules series features a modular design that offers flexibility for expansion. With its high throughput, fast speed and multiple parameters, the series helps to process a higher number of samples in the laboratory, improve diagnostic results and shorten turnaround time. The parameters on the iModules platform include dsDNA IgG, SSA IgG, SSB IgG, RNP70 IgG, Sm IgG, Jo-1 IgG, Scl-70 IgG, anti-CCP, MPO IgG, PR3 IgG, Cardiolipin IgG/IgA/IgM/total and β2 Glycoprotein IgG/IgA/IgM/total, etc., providing more accurate and reliable quantitative results.
Related Links:
Shenzhen YHLO Biotech Co., Ltd.
Peking Union Medical College Hospital
PUMCH, founded by the Rockefeller Foundation in 1921, has been designated by China’s Ministry of Health as one of the most authoritative centers for diagnosis and treatment of complex diseases. PUMCH’s department of Rheumatology and Immunology is the earliest dedicated department for rheumatology and immunology in China. The department’s laboratory is capable of diagnosing nearly 100 kinds of auto-antibodies, making it one of the largest auto-antibody diagnosing centers in China. In August 2020, the department upgraded its laboratory from the traditional ELISA technology to CLIA technology with the cooperation of YHLO.
With the help of YHLO’s iModules Integration System for Immunoassay, PUMCH has become the first among the top Chinese hospitals to establish a fully automated assembly line. YHLO’s iModules series features a modular design that offers flexibility for expansion. With its high throughput, fast speed and multiple parameters, the series helps to process a higher number of samples in the laboratory, improve diagnostic results and shorten turnaround time. The parameters on the iModules platform include dsDNA IgG, SSA IgG, SSB IgG, RNP70 IgG, Sm IgG, Jo-1 IgG, Scl-70 IgG, anti-CCP, MPO IgG, PR3 IgG, Cardiolipin IgG/IgA/IgM/total and β2 Glycoprotein IgG/IgA/IgM/total, etc., providing more accurate and reliable quantitative results.
Related Links:
Shenzhen YHLO Biotech Co., Ltd.
Peking Union Medical College Hospital
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Latest Industry News
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
Channels
Clinical Chemistry
view channel
New Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read more
Molecular Diagnostics
view channel
Blood Test Could Spot Common Post-Surgery Condition Early
Heterotopic ossification (HO), the abnormal formation of bone in soft tissue, is a common complication following hip replacement surgery. The condition affects nearly one in three patients and can lead... Read more
New Blood Test Can Help Predict Testicular Cancer Recurrence
Stage 1 testicular germ cell tumor is typically treated with surgery followed by active surveillance. Although most patients experience strong long-term outcomes, about one in four will see their cancer... Read more
New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood
Alzheimer’s disease begins developing years before memory loss or other symptoms become visible. Misfolded proteins gradually accumulate in the brain, disrupting normal cellular processes.... Read more
New Diagnostic Markers for Multiple Sclerosis Discovered in Cerebrospinal Fluid
Multiple sclerosis (MS) affects nearly three million people worldwide and can cause symptoms such as numbness, visual disturbances, fatigue, and neurological disability. Diagnosing the disease can be challenging... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read more
Pathology
view channel
World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
Blood sampling is one of the most common clinical procedures, but it can be difficult or uncomfortable for many patients, especially older adults or individuals with certain medical conditions.... Read more
Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
Polymerase Chain Reaction (PCR) testing became widely recognized during the COVID-19 pandemic as a powerful method for detecting viruses such as SARS-CoV-2. PCR belongs to a group of diagnostic methods... Read more
Technology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
